{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:57:03Z","timestamp":1774936623639,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ophtha.2024.12.035","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T02:06:59Z","timestamp":1735092419000},"page":"733-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chalazion and Hordeolum Development in Patients with Cystic Fibrosis on Elexacaftor\/Ttezacaftor\/Ivacaftor Therapy"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-1872","authenticated-orcid":false,"given":"Malcolm M.","family":"Kates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Luckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Vicinanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ophtha.2024.12.035_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2024.12.035_bib2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ophtha.2024.12.035_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.ophtha.2024.12.035_bib4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.ophtha.2024.12.035_bib5","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.ophtha.2024.12.035_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamadermatol.2022.5208","article-title":"Acneiform eruption following elexacaftor-tezacaftor-ivacaftor treatment in patients with cystic fibrosis","volume":"159","author":"Okroglic","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.12.035_bib7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1167\/iovs.15-17945","article-title":"Characterization of rat meibomian gland ion and fluid transport","volume":"57","author":"Yu","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024007991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024007991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:28:50Z","timestamp":1774344530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024007991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0161642024007991"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.035","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chalazion and Hordeolum Development in Patients with Cystic Fibrosis on Elexacaftor\/Ttezacaftor\/Ivacaftor Therapy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}